Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1990 3
1991 1
1995 1
1999 1
2001 4
2002 3
2004 4
2005 1
2006 4
2007 1
2008 1
2009 1
2010 3
2011 2
2012 3
2013 3
2014 3
2015 2
2017 1
2018 1
2019 2
2020 6
2021 4
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Edoxaban versus warfarin in patients with atrial fibrillation.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Giugliano RP, et al. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. N Engl J Med. 2013. PMID: 24251359 Free article. Clinical Trial.
International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors.
Kuan EC, Wang EW, Adappa ND, Beswick DM, London NR Jr, Su SY, Wang MB, Abuzeid WM, Alexiev B, Alt JA, Antognoni P, Alonso-Basanta M, Batra PS, Bhayani M, Bell D, Bernal-Sprekelsen M, Betz CS, Blay JY, Bleier BS, Bonilla-Velez J, Callejas C, Carrau RL, Casiano RR, Castelnuovo P, Chandra RK, Chatzinakis V, Chen SB, Chiu AG, Choby G, Chowdhury NI, Citardi MJ, Cohen MA, Dagan R, Dalfino G, Dallan I, Dassi CS, de Almeida J, Dei Tos AP, DelGaudio JM, Ebert CS, El-Sayed IH, Eloy JA, Evans JJ, Fang CH, Farrell NF, Ferrari M, Fischbein N, Folbe A, Fokkens WJ, Fox MG, Lund VJ, Gallia GL, Gardner PA, Geltzeiler M, Georgalas C, Getz AE, Govindaraj S, Gray ST, Grayson JW, Gross BA, Grube JG, Guo R, Ha PK, Halderman AA, Hanna EY, Harvey RJ, Hernandez SC, Holtzman AL, Hopkins C, Huang Z, Huang Z, Humphreys IM, Hwang PH, Iloreta AM, Ishii M, Ivan ME, Jafari A, Kennedy DW, Khan M, Kimple AJ, Kingdom TT, Knisely A, Kuo YJ, Lal D, Lamarre ED, Lan MY, Le H, Lechner M, Lee NY, Lee JK, Lee VH, Levine CG, Lin JC, Lin DT, Lobo BC, Locke T, Luong AU, Magliocca KR, Markovic SN, Matnjani G, McKean EL, Meço C, Mendenhall WM, Michel L, Na'ara S, Nicolai P, Nuss DW, Nyquist GG, Oakley GM, Omura K, Orlandi RR, … See abstract for full author list ➔ Kuan EC, et al. Int Forum Allergy Rhinol. 2024 Feb;14(2):149-608. doi: 10.1002/alr.23262. Epub 2024 Jan 2. Int Forum Allergy Rhinol. 2024. PMID: 37658764 Review.
Lessons Learned from Phase II and Phase III Trials Investigating Therapeutic Agents for Cerebral Ischemia Associated with Aneurysmal Subarachnoid Hemorrhage.
Qureshi AI, Lobanova I, Huang W, Ishfaq MF, Broderick JP, Cassarly CN, Martin RH, Macdonald RL, Suarez JI. Qureshi AI, et al. Neurocrit Care. 2022 Apr;36(2):662-681. doi: 10.1007/s12028-021-01372-4. Epub 2021 Dec 23. Neurocrit Care. 2022. PMID: 34940927 Review.
The following therapeutic agents were evaluated in the selected phase II and phase III trials: intravenous tirilazad, intravenous nicardipine, intravenous clazosentan, intravenous magnesium, oral statins, and intraventricular nimodipine. ...
The following therapeutic agents were evaluated in the selected phase II and phase III trials: intravenous tirilazad, intravenous nicardi …
Outcomes of Intensive Systolic Blood Pressure Reduction in Patients With Intracerebral Hemorrhage and Excessively High Initial Systolic Blood Pressure: Post Hoc Analysis of a Randomized Clinical Trial.
Qureshi AI, Huang W, Lobanova I, Barsan WG, Hanley DF, Hsu CY, Lin CL, Silbergleit R, Steiner T, Suarez JI, Toyoda K, Yamamoto H; for ATACH-II trial investigators. Qureshi AI, et al. JAMA Neurol. 2020 Nov 1;77(11):1355-1365. doi: 10.1001/jamaneurol.2020.3075. JAMA Neurol. 2020. PMID: 32897310 Free PMC article. Review.
Patients with intracerebral hemorrhage and initial systolic blood pressure of 180 mm Hg or more, randomized within 4.5 hours after symptom onset, were included. INTERVENTIONS: Intravenous nicardipine infusion titrated to goals. MAIN OUTCOMES AND MEASURES: Neurological dete …
Patients with intracerebral hemorrhage and initial systolic blood pressure of 180 mm Hg or more, randomized within 4.5 hours after symptom o …
Pharmaceutical administration for severe hypertension during pregnancy: Network meta-analysis.
Deng NJ, Xian-Yu CY, Han RZ, Huang CY, Ma YT, Li HJ, Gao TY, Liu X, Zhang C. Deng NJ, et al. Front Pharmacol. 2023 Jan 9;13:1092501. doi: 10.3389/fphar.2022.1092501. eCollection 2022. Front Pharmacol. 2023. PMID: 36699058 Free PMC article.
According to the SUCRA, diazoxide showed the best therapeutic effect, followed by nicardipine, nifedipine, labetalol, and nitroglycerine. The three pharmaceuticals with the worst therapeutic effect were ketanserin, hydralazine, and urapidil. It is worth noting that the hig …
According to the SUCRA, diazoxide showed the best therapeutic effect, followed by nicardipine, nifedipine, labetalol, and nitroglycer …
Comparison of intermittent versus continuous infusion antihypertensives in acute ischemic stroke.
Kamp A, Huang W, Lassiter T, Shah S, Liu B, Kram B. Kamp A, et al. Am J Emerg Med. 2022 Feb;52:220-224. doi: 10.1016/j.ajem.2021.11.037. Epub 2021 Nov 29. Am J Emerg Med. 2022. PMID: 34959025 Free PMC article.
The purpose of this study was to determine if an intermittent (labetalol or hydralazine) or continuous infusion (nicardipine or clevidipine) antihypertensive strategy facilitated timelier alteplase administration. ...
The purpose of this study was to determine if an intermittent (labetalol or hydralazine) or continuous infusion (nicardipine or clevi …
Early Hyperchloremia is Independently Associated with Death or Disability in Patients with Intracerebral Hemorrhage.
Qureshi AI, Huang W, Hanley DF, Hsu CY, Martin RH, Malhotra K, Steiner T, Suarez JI, Yamamoto H, Toyoda K. Qureshi AI, et al. Neurocrit Care. 2022 Oct;37(2):487-496. doi: 10.1007/s12028-022-01514-2. Epub 2022 May 5. Neurocrit Care. 2022. PMID: 35513751
Patients with one occurrence of hyperchloremia (odds ratio [OR] 2.5, 95% confidence interval [CI] 1.1-5.5) and those with two or more occurrences (OR 2.6, 95% CI 1.3-5.0) had significantly higher odds of death within 90 days after adjustment for age, race and ethnicity, National …
Patients with one occurrence of hyperchloremia (odds ratio [OR] 2.5, 95% confidence interval [CI] 1.1-5.5) and those with two or more occurr …
Systolic Blood Pressure Reduction and Acute Kidney Injury in Intracerebral Hemorrhage.
Qureshi AI, Huang W, Lobanova I, Hanley DF, Hsu CY, Malhotra K, Steiner T, Suarez JI, Toyoda K, Yamamoto H; Antihypertensive Treatment of Cerebral Hemorrhage 2 Trial Investigators. Qureshi AI, et al. Stroke. 2020 Oct;51(10):3030-3038. doi: 10.1161/STROKEAHA.120.030272. Epub 2020 Aug 25. Stroke. 2020. PMID: 32838673
In multivariate analysis, the higher baseline serum creatinine (110 mumol/L) was associated with AKI (odds ratio 2.4 [95% CI, 1.2-4.5]) and renal AEs (odds ratio 3.1 [95% CI, 1.2-8.1]). Higher area under the curve for intravenous nicardipine dose was associated with AKI (o …
In multivariate analysis, the higher baseline serum creatinine (110 mumol/L) was associated with AKI (odds ratio 2.4 [95% CI, 1.2-4.5]) and …
Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.
Zhou YT, Yu LS, Zeng S, Huang YW, Xu HM, Zhou Q. Zhou YT, et al. Ther Clin Risk Manag. 2014;10:17-26. doi: 10.2147/TCRM.S55512. Epub 2013 Dec 20. Ther Clin Risk Manag. 2014. PMID: 24379677 Free PMC article. Review.
RESULTS: There were three circumstances related to pharmacokinetic DDIs in the combined use of DHP-CCB and statin: 1) statin is comedicated as the precipitant drug (pravastatin-nimodipine and lovastatin-nicardipine); 2) statin is comedicated as the object drug (isradipine- …
RESULTS: There were three circumstances related to pharmacokinetic DDIs in the combined use of DHP-CCB and statin: 1) statin is comedicated …
A comprehensive map of disease networks and molecular drug discoveries for glaucoma.
Wang H, Deng Y, Wan L, Huang L. Wang H, et al. Sci Rep. 2020 Jun 16;10(1):9719. doi: 10.1038/s41598-020-66350-w. Sci Rep. 2020. PMID: 32546683 Free PMC article.
A subsequent analysis of the electronic medical records (EMRs) of 136,128 patients treated in Sichuan Provincial People's Hospital for candidate drug usage and the onset of glaucoma revealed nine candidate drugs. Among these drugs, individuals treated with nicardipine had …
A subsequent analysis of the electronic medical records (EMRs) of 136,128 patients treated in Sichuan Provincial People's Hospital for candi …
56 results